(IN BRIEF) China and Pakistan publicly reaffirmed their “ironclad” friendship and all-weather strategic partnership during a January 2026 meeting in Beijing, marking 75 years of diplomatic ties and pledging deeper cooperation under an upgraded CPEC 2.0, alongside mutual political support … Read the full press release
Posted in Economy, European Union, Government, International Trade, Law, Politics
Tagged Afghanistan analogy, Baloch Liberation Army, Balochistan, Beijing, Belt and Road Initiative, BLA, BRI, CHINA, China–Pakistan Economic Corridor, Chinese citizens, Chinese investments, counterterrorism, CPEC 2.0, Dasu hydropower project, foreign worker protection, ironclad friendship, ISIS-K, Islamic State Khorasan Province, jihadist networks, Karachi attack, Khyber Pakhtunkhwa, monopoly on violence, National People’s Congress, Pakistan, Pakistan internal security, Pakistan National Assembly, political stability, Radio Free Europe Radio Liberty, RFE RL, Sardar Ayaz Sadiq, security cooperation, security guarantees, separatist groups, Shangla attack, Sino-Pakistani relations, special security units, state fragility, strategic risk, Tehrik-e-Taliban Pakistan, territorial integrity, Terrorism, terrorist attacks, transnational terrorism, TTP, Zhao Leji
(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan has been accepted by the U.S. FDA for treating advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in patients who have previously received systemic therapies. The … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged advanced NSCLC, antibody-drug conjugate, AstraZeneca, Biologics License Application, BLA, breakthrough therapy designation, Daiichi Sankyo, datopotamab deruxtecan, drug approval, EGFR-mutated, EGFR-tyrosine kinase inhibitors, FDA, metastatic NSCLC, non-small cell lung cancer, NSCLC, objective response rate, oncology, partnership, Phase III Trials, Priority Review, safety profile, systemic therapies, TROP2-directed, TROPION-Lung01, TROPION-Lung05, TROPION-Lung14, TROPION-Lung15
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?